NCT05292664 - Venetoclax Basket Trial for High Risk Hematologic Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 29, 2023

Primary Completion Date

July 2, 2026

Study Completion Date

July 2, 2028

Conditions

Myelodysplastic Syndromes, de NovoMyelodysplastic Syndromes, SecondaryMyelodysplastic Syndromes, Previously TreatedTreatment-Related Acute Myeloid LeukemiaTherapy-Related Myelodysplastic SyndromeAcute Lymphoblastic Leukemia, in RelapseAcute Lymphoblastic Leukemia With Failed RemissionLymphoblastic Lymphoma, in RelapseLymphoblastic Lymphoma, RefractoryAcute Leukemia of Ambiguous Lineage in RelapseAcute Leukemia of Ambiguous Lineage

Interventions

DRUG

Venetoclax

Tablet taken orally

DRUG

Azacitidine

Taken intravenously

DRUG

Cytarabine

Lumbar Puncture

DRUG

Methotrexate

Lumbar Puncture

DRUG

Hydrocortisone

Lumbar Puncture

DRUG

Leucovorin

Taken Orally or intravenously

DRUG

Dexamethasone

Taken Orally or intravenously

DRUG

Vincristine

Taken intravenously

DRUG

Doxorubicin

Taken intravenously

DRUG

Dexrazoxane

Taken intravenously

DRUG

Calaspargase Pegol

Taken intravenously

DRUG

Erwinia asparaginase

Given as intramuscular injection

Trial Locations (5)

30329

Children's Healthcare of Atlanta at Arthur M. Blank Hospital, Atlanta

60611

Ann & Robert H Lurie Children's Hospital of Chicago, Chicago

80045

Children's Hospital Colorado, Aurora

94158

University of California San Francisco-Benioff Children's Hospital, San Francisco

02215

Dana-Farber Cancer Institute, Boston